Whalesbook
Dekho bhai, India mein jo naya generic semaglutide market khula hai na, April mein uski total sales ₹44 Crore thi. Aur Torrent Pharma ne kya kamaal kiya hai, pehle hi mahine mein 38% ka market share loot liya! Matlab ₹17 Crore ki sales sirf Torrent ki thi. Baaki jo 12+ competitors aaye the na patent expiry ke baad, woh sab milakar bhi Torrent ke saamne kam pad gaye. Zydus, Dr. Reddy's, Lupin jaise bade players bhi sirf ₹4 Crore ke aas paas hi the.
Is itni jaldi success ka raaz hai Torrent ka strategy. Yeh woh akeli Indian company hai jo generic semaglutide dono forms mein de rahi hai - ek toh muh se lene wali oral tablet aur doosra injectable. Patients ko oral waali zyada pasand aa rahi hai, aur Torrent ne patent se bachne ke liye smart hybrid technology use ki hai oral form ke liye. Is wajah se woh patent expiry ke baad bhi sabse pehle launch kar paye.
Aur sirf product hi nahi, Torrent ne Doctors se bhi achha connection banaya hai aur oral tablets aur injectable pens (reusable aur disposable dono) ke liye ek hi branding rakhi hai. Yeh doctors aur patients ke liye therapy manage karna aasan bana deta hai.
India ka anti-obesity market abhi ₹1,600 Crore ka hai aur lagbhag 18 mahine mein yeh ₹4,000 se ₹5,000 Crore tak ja sakta hai. Semaglutide agli do saal mein GLP-1 market ka 80% hissa capture kar sakta hai. Torrent ka market cap $12.5 billion hai, P/E ratio 64.25 hai, aur share price abhi ₹2700 ke aas paas hai. Wahi, competitors ke share prices dekho toh Dr. Reddy's ₹5800, Sun Pharma ₹1100, Zydus ₹950, aur Lupin ₹1050 ke aas paas chal rahe hain.
Haan, risks toh hain. Torrent ka jo 'hybrid technology' wala oral drug hai, woh future mein patent issues mein pad sakta hai. Competition bahut badh raha hai aur price kam karne ka pressure bhi aa sakta hai. Lekin abhi tak Torrent ne jo performance dikhai hai, woh zabardast hai aur yeh company India ke badhte diabetes aur weight management market mein ek bada player ban sakti hai. Abhi supply manage karna bhi ek challenge hoga.